Trial assessing individualized options for treatment for breast cancer: The TAILORx trial

Future Oncology

Volumn 4, Issue 5, 2008, Pages 603-610

  Zujewski, Jo Anne ^a   Kamin, Leah ^b  

^a Cancer Therapy Evaluation Program   (United States)

^b EMMES CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE RECEPTOR; METHOTREXATE; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; IN SITU HYBRIDIZATION; MASTECTOMY; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; TAMOXIFEN;

EID: 55249116037     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.5.603     Document Type: Article

References (55)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA. Cancer J. Clin. 58(2), 71-96 (2008).
2. Sparano JA, Fazzari MJ, Childs G: Clinical application of molecular profiling in breast cancer. Future Oncol. 1(4), 485-496 (2005).
3. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J. Clin. Oncol. 15(4), 1385-1394 (1997).
4. Fisher B, Dignam J, Wolmark N et al.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J. Natl. Cancer Inst. 89(22), 1673-1682 (1997).
5. Fisher B, Jeong JH, Dignam J et al.: Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J. Natl. Cancer Inst. Monogr. (30), 62-66 (2001).
6. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R: Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J. Clin. Oncol. 24(6), 872-877 (2006).
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Clarke M, Collins R et al.: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
8. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. Monogr. (30), 5-15 (2001).
9. Goldhirsch A, Coates AS, Gelber RD et al.: First - select the target: better choice of adjuvant treatments for breast cancer patients. Ann. Oncol. 17(12), 1772-1776 (2006).
10. Carlson RW, Brown E, Burstein HJ et al.: NCCN Task Force Report: adjuvant therapy for breast cancer. J. Natl. Compr. Canc. Netw. 4(Suppl. 1), S1-S26 (2006).
11. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol. 26(5), 721-728 (2008).
12. Paik S, Shak S, Tang G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
13. Taube SE, Jacobson JW, Lively TG: Cancer diagnostics: decision criteria for marker utilization in the clinic. Am. J Pharmacogenomics 5(6), 357-364 (2005).
14. Paik S, Tang G, Shak S et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24(23), 3726-3734 (2006).
15. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res. Treat. 52(1-3), 261-288 (1998).
16. Eifel P, Axelson JA, Costa J et al.: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. 93(13), 979-989 (2001).
17. Carlson RW, Edge SB, Theriault RL: NCCN: Breast cancer. Cancer Control 8(6 Suppl. 2), 54-61 (2001).
18. Goldhirsch A, Wood WC, Gelber RD et al.: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J. Clin. Oncol. 21(17), 3357-3365 (2003).
19. Fisher B, Jeong JH, Bryant J et al.: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364(9437), 858-868 (2004).
20. Proceedings of the 9th International Conference on Primary Therapy of Early Breast Cancer. January 26-29, 2005. St. Gallen, Switzerland. Breast 14(6), 427-642 (2005).
21. Sorlie T, Wang Y, Xiao C et al.: Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7, 127 (2006).
22. Sorlie T, Tibshirani R, Parker J et al.: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003).
23. Van de Vijver MJ, He YD, van't Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
24. Wang Y, Klijn JG, Zhang Y et al.: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 (9460), 671-679 (2005).
25. Liu R, Wang X, Chen GY et al.: The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007).
26. Fan C, Oh DS, Wessels L et al.: Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355(6), 560-569 (2006).
27. Marchionni L, Wilson RF, Wolff AC et al.: Systematic review: gene expression profiling assays in early-stage breast cancer. Ann. Intern. Med. 148(5), 358-369 (2008).
28. Esteva FJ, Sabin AA, Cristofanilli M et al.: Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11(9), 3315-3319 (2005).
29. Habel L, Shak S, Jacobs MK et al.: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 8(3), R25 (2006).
30. Lo SS, Norton J, Mumby PB et al.: Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. J. Clin. Oncol. 25 (2007 ASCO Annual Meeting Proceedings [Post-Meeting Edition]) (2007).
31. Kamal AH, Loprinzi CL, Reynolds C et al.: How well do standard prognostic criteria predict oncotype DX (ODX) scores? J. Clin. Oncol. 25 (2007 ASCO Annual Meeting Proceedings [Post-Meeting Edition]), 576 (2007).
32. Hudis CA, Barlow WE, Costantino JP et al.: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J. Clin. Oncol. 25(15), 2127-2132 (2007).
33. Albain KBW, O'Malley F, Siziolpikou K et al.: Concurrent versus sequential chemohormonal therapy versus tamoxfien alone for postmenopausal, node-positive, ER and/or PgR-positive breast cancer: mature outcomes and new biologic correlates on Phase III intergroup trial 0100 (S8814). Breast Cancer Res. Treat. 90, 195 (2005).
34. Ravdin PM, Siminoff LA, Davis GJ et al.: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 19(4), 980-991 (2001).
35. Bryant J: Toward a more rational selection of tailored adjuvant therapy [Poster presentation]. Presented at: 9th International St. Gallen Oncology Conference. St. Gallen, Switzerland, 26-29 January 2005.
36. Goldstein LJ, Gray R, Badve S et al.: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J. Clin. Oncol. 26(25), 4063-4071 (2008).
37. Habel L, Achacoso N, Maddala T et al.: Estrogen receptor and breast cancer survival in a Kaiser permanente population-based study: comparison of quantitative reverse transcriptase polymerase chain reaction and immunohistochemistry [Poster #5029]. Presented it: 30th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13-16 December 2007.
38. Habel LA, Stanford JL: Hormone receptors and breast cancer. Epidemiol. Rev. 15(1), 209-219 (1993).
39. Collins LC, Achacoso NA, Nekhlyudov L et al.: Clinical and pathologic features of ductal carcinoma in situ associated with the presence of flat epithelial atypia: an analysis of 543 patients. Mod. Pathol. 20(11), 1149-1155 (2007).
40. Haibe-Kains B, Desmedt C, Piette F et al.: Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics 9, 394 (2008).
41. Mook S, Schmidt MK, Viale G et al.: The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res. Treat. PMID: 18661261 (2008) (Epub ahead of print).
42. Cardoso F, Saghatchian M, Thompson A, Rutgers E: Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 26(12), 2058-2059; author reply 2060-2051 (2008).
43. de Azambuja E, Cardoso F, Meirsman L et al.: The new generation of breast cancer clinical trials: the right drug for the right target. Bull. Cancer 95 (3), 352-357 (2008).
44. Dinh P, Cardoso F, Sotiriou C, Piccart-Gebhart MJ: New tools for assessing breast cancer recurrence. Cancer Treat. Res. 141, 99-118 (2008).
45. Cardoso F, Van't Veer L, Rutgers E et al.: Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26(5), 729-735 (2008).
46. Widakowich C, de Azambuja E, Gil T et al.: Molecular targeted therapies in breast cancer: where are we now? Int. J. Biochem. Cell Biol. 39(7-8), 1375-1387 (2007).
47. Bernard-Marty C, Cardoso F, Sotiriou C, Piccart MJ: Towards an individualization of systemic treatment of breast tumors. Bull. Cancer 93(8), 791-797 (2006).
48. Buyse M, Loi S, van't Veer L et al.: Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98(17), 1183-1192 (2006).
49. Loi S, Sotiriou C, Buyse M et al.: Molecular forecasting of breast cancer: time to move forward with clinical testing. J. Clin. Oncol. 24(4), 721-722; author reply 722-723 (2006).
50. Colozza M, Azambuja E, Cardoso F et al.: Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Oncol. 16(11), 1723-1739 (2005).
51. Cardoso F: Show me the genes - I will tell you who/how to treat! Breast Cancer Res. 7(2), 77-79 (2005).
52. Loi S, Desmedt C, Cardoso F, Piccart M, Sotiriou C: Breast cancer gene expression. profiling: clinical trial and practice implications. Pharmacogenomics 6(1), 49-58 (2005).
53. Sparano J: The TAILORx trial: individualized options for treatment. Commun. Oncol. 3(8), 494-496 (2006).
54. Sparano J: Design of and Rationale for the Trial Assigning Individualized Options for Treatment (TAILORx). ASCO Educational Book, Alexandria, VA, USA (2007).
55. Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer 7(4), 347-350 (2006).